Open AccessPatritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
Author(s) -
Kumiko Koyama,
H Ishikawa,
Manabu Abe,
Yoshinobu Shiose,
Suguru Ueno,
Yang Qiu,
Kenji Nakamaru,
Masato Murakami
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0267027
Subject(s) - cancer research , antibody , mutant , hek 293 cells , cell culture , cell growth , cell , cancer , in vitro , biology , antibody drug conjugate , cancer cell , erbb3 , chemistry , microbiology and biotechnology , monoclonal antibody , gene , immunology , biochemistry , epidermal growth factor receptor , genetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom